NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations

Table 2 NAT2 genotype frequencies among 100 gastric cancer patients and 100 controls, and gastric cancer risk

Genotype	Patients	Controls	OR	95% CI
Rapid
#4#4	1	4	0.3	0.01-2.4
#12B#12B		1
#12#12		1
Intermediate
#4#5B	14	10	1.4	0.6-3.6
#4#6A	6	4	1.5	0.4-6.6
#4#6B		3
#5B#13	1	1
#6A#12C	2
#6B#13	2
#12#6B	1
#12#7B	1
#12C#6A		2
#12C#6B		1
Slow
#5A#6A	2	1
#5B#5B	18	13	1.4	0.6-3.2
#5B#5C	2	2
#5B#6A	19	13	1.5	0.6-3.3
#5B#6B	2	4	1
#5B#7A	1	1
#5B#7B	4	1	1
#5C#5A	2
#5C#5C	2	1
#5C#6A	4	4
#5C#7B	1
#6A#6A	4	11	0.4	0.1-1.3
#6A#7B	1	4
#6C#6C	5	4
#7A#7A	1	2
#7A#11A	1	2
#6A#6C	5	4
#7B#7B	1	1
#5D#5D, #5D#7A, #5D#7B, #6#7B, #7B#5A, #7B#6B, #5C#6B		71

¹Each of these genotypes had an incidence of one per genotype.